*All times listed are Central European Time (CET)
Conference Day 2
Thursday 7th December 2023
8:00 am Registration
8:50 am Opening Remarks
Choosing the Correct Target Molecule of Your TRP to Ensure Accuracy With Tumour Targeting
9:00 am 225Ac-Targeted Therapy: Advancing Antibody & Small Molecule-Based Agents into the Clinic
Synopsis
• Uncover the power of targeted radiotherapy over targeted chemotherapy
• Why is 225Ac an attractive radioisotope for targeted therapy?
• Discuss the advantages and challenges of antibody-based radiotherapy
9:30 am Panel Discussion: Comparing Antibodies, Peptides & Small Molecules as Targeting Molecules to Improve Stability & Accuracy of Your TRP
Synopsis
• Highlighting the advantages of antibodies, peptides and small molecules
• Understanding the difference each makes to the final TRP
• Analysing which molecule to choose depending on your target
10:15 am Delving Into Bicycles® as Agents for Radionuclide Delivery to Tumours
Synopsis
• Introduction to Bicycles and their properties
• Evaluating Bicycles as agents for radionuclide delivery to tumours
• Exploring a case study on using Bicycles as agents
10:45 am Precision Targeting – Affilin®-based Radiotheranostics
Synopsis
- Affilin® Radiotheranostics – breaking paradigms in RLT
- Best-in-class potential, outperforming current benchmarks
- Full modularity and engineering for fast innovation
- AI-driven Therapeutic development
11:00 am Morning Networking Break
Delving into Isotopes to Maximise the Efficacy of Your TRP
11:30 am Advancing Universal Targeted Radiotherapies: Unleashing the Potential of Alpha & Beta Particles for Solid & Hematologic Malignancies
Synopsis
• Understanding the value of a universal targeting agent
• Validating with beta emitters in hematology oncology
• Exploring its use with alpha emitters for difficult to treat solid tumours
12:00 pm Actinium-225: Fostering the Future of Targeted Alpha Therapy
Synopsis
• Understand the importance of choosing the right isotope pair and how the future of TRT
depend on isotope availability
12:30 pm Lunch
1:30 pm Understanding Radionuclide Auger Therapy to Examine Its Use & Advantages
Synopsis
• Identifying which radioisotopes can be used for Auger therapy
• Overview of Auger therapies to date
• Examining Auger PARP inhibitor radionuclide therapy
2:00 pm MACROPA™ – The Ring for Life or Keeping the Ac-225 Pay-Load on Your Targeting Vector
Synopsis
- MACROPA™ offers the possibility to label at room temperature and tolerates other metals being present during and post labeling
- MACROPA™ forms stable complexes holding the radioactive payload(s) for several days on the targeting vector
- MACROPA™ re-complexes formed (decay) Bi-213 (the only relevant daughter isotope) in the drug product vial over the shelf-life of the DP, allowing for a better controlled/defined radiopharmaceutical with minimal radioactive contaminants
2:30 pm Afternoon Networking Break
Driving Clinical Translational of Your TRP to Optimise In-Human Studies
3:00 pm Preclinical Characterisation of a Novel 68Ga/177Lu-Labeled Fibroblast Activation Protein (FAP) Targeted Peptide Binder for Cancer Imaging & Therapy
Synopsis
• NT6020 is a potent and specific novel peptide binder to FAP.
• 177Lu-NT6020 demonstrates efficient and continued tumour uptake with fast renal clearance, and minimal normal tissue uptake.
• 177Lu-NT6020 significantly inhibits tumour growth in FAP-expressing HEK293 xenograft model.
3:30 pm Computational Modelling in Radiopharmaceutical Therapy
Synopsis
• Review mechanistic modeling for radiobiology of RPT (cellular and molecular radiation interactions)
• Evaluate dosimetry for RPT
• Analyse imaging-based biodistributions of radiopharmaceuticals
4:00 pm Bench to Bedside – How to Design Innovative Radiopharmaceuticals for Human Use
Synopsis
• Beyond high affinity: clinically viable biodistribution
• Cat and mouse: Preclinical screening and optimisation
• Compassionate phase 0?: Leveraging unique attributes of radiopharmaceuticals
4:30 pm Bridging the Gap Between Preclinical Studies and Clinical Development – Fih Phase 0 Studies
Synopsis
- Exploring the Role of Phase 0 Studies: Understanding the significance of Phase 0 studies in the development of targeted radiopharmaceuticals (TRP) and their role as a crucial intermediate step between preclinical research and Phase 1/2 clinical trials
- Advantages and Challenges: Discussing the advantages and challenges associated with conducting Phase 0 studies, including their potential to accelerate drug development, provide early human data, and optimize in-human studies while managing risks effectively
- Conducting, and interpreting Phase 0 studies for TRPs, emphasizing their impact on decision-making and successful translation to clinical trials
5:00 pm Chair’s Closing Remarks
5:15 pm End of Conference
